BCM
PCRX icon

Bienville Capital Management’s Pacira BioSciences PCRX Stock Holding History

Bienville Capital Management’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-3,500
Closed -$310K – 83
2014
Q4 		$310K Buy
+3,500
New +$331K 0.26% 59

Other funds holding PCRX

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MCM
Marsico Capital Management Denver, Colorado $3.4B AUM 51.58% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bienville Capital Management's PCRX Position: Q1 2015 in Review

Bienville Capital Management sold out of Pacira BioSciences (PCRX) in Q1 2015, closing a stake of 3,500 shares — an estimated $310K sold.

Bienville Capital Management first reported a position in PCRX in Q4 2014 and held it in 1 quarter. The position peaked at $310K in Q4 2014. 205 funds tracked by Wall St. Rank hold PCRX as of Q1 2015.

  • Bienville Capital Management reported no remaining Pacira BioSciences position as of Q1 2015 after selling out during the quarter.
  • Bienville Capital Management sold 3,500 Pacira BioSciences shares in Q1 2015, an estimated $310K.
  • Bienville Capital Management first reported a position in Pacira BioSciences in Q4 2014 and held it in 1 quarter.
  • Bienville Capital Management's Pacira BioSciences position peaked at $310K in Q4 2014.
  • 205 funds tracked by Wall St. Rank held Pacira BioSciences as of Q1 2015.

Based on Bienville Capital Management's 13F filing for Q1 2015, filed 13 May 2015.